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Abstract
Matrix metalloproteinase-1 (MMP-1) breaks down interstitial collagens, a major component of stromal tissue and a
barrier for invading tumor cells. The degradation of collagen by MMP-1 may, therefore, provide one mechanism for
facilitating tumor invasion and metastasis. Because of the potential for excessive matrix degradation, the expression of
MMP-1 is tightly regulated, often by the mitogen-activated protein kinase (MAPK) pathway. The MAPK signal cascade
consists of three separate pathways, the extracellular response kinase (ERK), p38 and Jun N-terminal kinase, which target
proteins of the AP-1 and ETS families transcription of the gene. The MMP-1 promoter contains a single nucleotide
polymorphism (SNP) at 31607 bp, which creates an ETS binding site by the addition of a guanine (5P-GGAT-3P or ‘2G
SNP’) compared to the 1G SNP (5P-GAT-3P), and enhances MMP-1 transcription. A2058 melanoma cells represent one
tumor cell line that is homozygous for the 2G allele and that produces constitutively high levels of MMP-1. Thus, we used
these cells to define the mechanism(s) responsible for this high level of expression. We show that inhibition of ERK 1/2 leads
to the repression of MMP-1 transcription, and that both the 2G polymorphism and the adjacent AP-1 site at 31602 bp are
necessary for high levels of MMP-1 transcription and for the inhibition of MMP-1 expression by PD098059, a specific ERK
inhibitor. Furthermore, restoration of MMP-1 levels after ERK 1/2 inhibition requires de novo protein synthesis of a factor
necessary for MMP-1 expression. Thus, this study suggests that the ERK 1/2 pathway targets the 2G polymorphism, and
that the continuous synthesis of a protein(s) is necessary for the constitutive expression of MMP-1. ß 2002 Published by
Elsevier Science B.V.
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1. Introduction
The matrix metalloproteinase (MMP) family con-
sists of at least 23 zinc-dependent proteases that to-
gether degrade the various components of the extra-
cellular matrix (ECM) [1]. The MMP family is
further subdivided into four main groups: the inter-
stitial collagenases, gelatinases, stromelysins and
membrane-bound type. One member of the intersti-
tial collagenases is matrix metalloproteinase-1
(MMP-1), which can degrade type I, II, and III col-
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lagens [1]. In most normal cells, physiologic levels of
MMP-1 are low, but in pathologic states, such as
tumor invasion and metastasis, there may be dysre-
gulation of MMP-1, leading to constitutively high
expression [2^5]. For tumor cells to metastasize
they must degrade the type IV collagen in basement
membrane, which is cleaved by MMP-2 and MMP-9.
Once past the basement membrane, however, tumor
cells need to invade through the interstitial stroma
(collagens I, III) to reach the vasculature and dissem-
inate to distant sites. High constitutive expression of
MMP-1 can facilitate this invasive step, thus increas-
ing the metastatic potential of tumor cells. Indeed,
the prognosis of patients with tumors expressing high
levels of MMP-1 is poorer than those expressing low
levels (reviewed in [3]), suggesting that tumors pro-
ducing high levels of this enzyme have a more ag-
gressive, metastatic phenotype.
MMP-1 can be induced by many physiological
stimuli, including cytokines, growth factors and phor-
bol esters [5,6]. The mechanisms controlling the tran-
scriptional induction of MMP-1 have been studied in
detail [5,7,8]. Induction of MMP-1 transcription dur-
ing wound healing [9] or in rheumatoid arthritis [5] is
largely mediated by in£ammatory cytokines (e.g.
IL-1, TNF), whereas in development, stromal tissue
formation is largely mediated by growth factors, such
as bFGF [7] and EGF [10]. For both cytokines and
growth factors, induction of MMP-1 occurs through
activation of multiple signaling pathways. One im-
portant component of these pathways is the mito-
gen-activated protein kinases (MAPK), and a grow-
ing body of evidence supports the role of the MAPK
pathways in the transcriptional regulation of MMP-1
[5,11,12]. The MAPK consists of three pathways: the
extracellular response kinase (ERK), p38 and Jun N-
terminal kinase (JNK). The p38 and JNK pathways
are activated in response to stress [13], while the ERK
pathway is activated by growth factors, usually
through Ras, a commonly mutated oncoprotein in
cancer [14]. The MAPK pathways target the AP-1
and ETS/PEA3 transcription factor families, which
are important regulators of many MMPs [11,12,
15,16]. Most MMPs contain an AP-1 site at approx-
imately 370 bp and this site is important in both
basal and induced transcription [5,6,16^18]. In addi-
tion, an ETS site is located upstream at 389 bp, and
these AP-1 and ETS sites cooperate to regulate tran-
scription [19]. Mutation of this AP-1 site in the
MMP-1 promoter reduces basal expression and pre-
vents induction by bFGF [19], IL-1 [5] and phorbol
esters [16]. Similarly, AP-1/ETS sites in the stromely-
sin promoter must act in concert to induce transcrip-
tion [16], suggesting that AP-1 and adjacent ETS site
are crucial in the regulation of MMPs.
One potential target of these signaling pathways in
the MMP-1 promoter is a single nucleotide polymor-
phism (SNP) at 31607 bp, in which the DNA se-
quence is either 5P-GAA-3P (1G) or 5P-GGAA-3P
(2G) [20]. The 2G DNA contains the consensus bind-
ing site for the ETS family of transcription factors,
and is adjacent to an AP-1 consensus sequence at
31602 bp. We have found that there is increased
transcription from the 2G SNP compared to the
1G [20], and that tumors with the 2G allele produce
higher levels of MMP-1 [20,21]. In addition, the 2G
allele has been linked to the progression of malignant
melanoma [22], to the incidence of ovarian [23] and
endometrial cancers [21], and to the invasiveness of
colorectal cancer [24]. In contrast to normal cells that
produce low basal levels of MMP-1, some tumor
cells, such as the A2058 melanoma cells, have high
levels of constitutive expression [20,25,26]. A2058
melanoma cells are an aggressive line established
from a brain metastasis and are homozygous for
the 2G allele [25]. However, little is known about
the factors controlling the high level of expression
of MMP-1 in these cells.
In this paper, we studied the signaling pathways
that are involved in the expression of MMP-1 in the
A2058 melanoma cells, and we examined cis-acting
sequences in the promoter through which these path-
ways may mediate their e¡ects. Our results indicate
that inhibiting the ERK 1/2 MAPK pathway, which
targets the upstream AP-1 and ETS sites in the 2G
promoter, reduces the levels of MMP-1. They also
suggest that the Ras/Mek/Erk pathway is involved in
the continuous production of a protein(s) necessary
for this high expression of MMP-1.
2. Materials and methods
2.1. Cell culture
Stock cultures of A2058 melanoma cells were
BBADIS 62088 26-4-02
G.B. Tower et al. / Biochimica et Biophysica Acta 1586 (2002) 265^274266
grown in 150 mm culture plates in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM) containing 10% FCS,
L-glutamine, and penicillin/streptomycin (37‡C in 5%
CO2), and passaged when they reach con£uence [20].
For most experiments, con£uent cultures of cells
were washed two times with Hanks’ balanced salt
solution (HBSS) to remove traces of serum and cul-
tured in serum-free DMEM with 0.2% actalbumin
hydrolysate (LH) (DMEM/LH). Cells were treated
with cycloheximide (Sigma) at 10 Wg/ml, varying con-
centrations of PD098059 and U0126 (Calbiochem),
inhibitors of the ERK 1/2 pathway or SB203580
(Calbiochem), an inhibitor of the p38 pathway. All
compounds were solubilized in DMSO.
2.2. Northern blot analysis
Total RNA (10 Wg) was harvested from cells with
Trizol (Gibco) and separated on a 5% formaldehyde
gel, transferred to a GeneScreen membrane (NEN
Life Sciences) and probed with K-32P-labeled cDNAs
for MMP-1, -2, -9 [26] and MT1-MMP [16]. Levels
of GAPDH mRNA or 28S rRNA controlled for
loading.
2.3. Western blot analysis
Whole cell lysates were harvested by mechanical
scraping and collected with 2USDS bu¡er [27]. Pro-
teins were separated on 10% Tris^HCl Ready Gels
(Bio-Rad) and transferred to Immobilon-P PVDF
membranes (Millipore). All membranes were blocked
in 5% dry milk (Carnation) at room temperature
for 1 h. Blots were probed with antibodies against
phospho-p42/44 (pp42/44) and total p42/44 (Cell
Signaling) overnight at 4‡C, as suggested by the
manufacturer. Proteins were visualized by enhanced
chemiluminescence (ECL).
2.4. Transient transfection and luciferase assay
One microgram of DNA from promoter constructs
from MMP-1 (4372 bp) containing either 1G or 2Gs
at 31607 bp, linked to luciferase reporter [20], was
transiently transfected into cells using Geneporter
(Gene Therapy Systems). Following recovery, cells
were washed and incubated with serum-free medium,
with or without PD98059, for 24 h, and cell lysates
were then assayed for luciferase activity in a lumin-
ometer. Mutational and deletional analyses were
used to identify target sequences of the signal/trans-
duction inhibitors. All transfections were carried out
in triplicate; cells were co-transfected with 25 ng of a
CMV-Renilla luciferase construct (Promega) to con-
trol for transfection e⁄ciency and data were normal-
ized to this constant.
2.5. PCR-based site-directed mutagenesis
Mutation of the 2G MMP-1 construct containing
the mutant AP-1 site at 31602 bp has been previ-
ously described [20]; the sequence accession number
is AF023338. To construct the 1G MMP-1 promoter
with a mutated AP-1 site at 31602 bp, the wild-type
site was changed from 5P-TGACTTA-3P to the mu-
tant form 5P-GTCATTA-3P. An AatII site is located
5P to the site and an EcoRV site is located 3P, which
allowed for digestion of £anking sequences and sub-
sequent ligation into a previously digested MMP-1
pGL3 construct with ends compatible with the di-
gested fragment. The AatII sense primer was 5P-CA-
GTGTATGAGACTCTTCC-3P and the EcoRV anti-
sense primer was 5P-CAGTGGAGAAACACTGGC-
3P. The two primers used to make the mutated site
were sense 5P-TTAGAAAGATAGTCATTATCTC-
AAAT-3P, and antisense 5P-ATTTGAGATAATG-
ACTATCTTTCTAA-3P. The sense and the EcoRV
primers were used to generate a mutant product of
202 bp, and the antisense and the AatII primers were
used to generate a mutant fragment of 405 bp. The
products of these reactions were combined and used
as the template for the AatII and the EcoRV primers
to create the ¢nal fragment containing the mutant
AP-1 site. The 455 bp product was excised, puri¢ed,
and analyzed by agarose gel electrophoresis. Muta-
genesis was con¢rmed by DNA sequencing.
3. Results
3.1. Constitutive MMP-1 expression is ERK 1/2
dependent
The MEK/ERK pathway is often dysregulated in
tumors [28] and we hypothesized that this dysregula-
tion may a¡ect the expression of MMP-1. To deter-
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mine whether the constitutive expression of MMP-1
is dependent on this MAPK pathway, A2058 mela-
noma cells were treated with increasing concentra-
tions (1^20 WM) of PD98059, a speci¢c inhibitor of
MEK 1/2 activation [29]. After 24 h treatment,
MMP-1 mRNA was analyzed. Fig. 1A shows that
levels of MMP-1 mRNA were inhibited in a dose-
dependent manner, with total inhibition at 5 WM. To
examine the speci¢city of inhibition by PD098059,
we analyzed other MMPs that are also constitutively
expressed by these cells [26]. Expression of MMP-9, a
gene important in the destruction of the basement
membrane (type IV collagen) that is often regulated
by the MAPK pathways [30], was minimally down-
regulated when normalized to GAPDH mRNA,
although only at concentrations of 10 and 20 WM
(data not shown). Two other MMPs, MMP-2 and
MT1-MMP, another type IV collagenase and a
membrane-bound form of these enzymes, respec-
tively, were una¡ected by PD098059 (data not
shown). Thus, the inhibition of MMP-1 by 5 WM
of PD098059 was speci¢c. To support ¢ndings that
the ERK pathway is involved, U0126, another inhib-
itor of the ERK pathway, which non-competitively
inhibits MEK function [31], was also used. MMP-1
mRNA levels were inhibited at 5 WM U0126 (Fig.
1C), similar to the e¡ects with PD098059.
Phosphorylation of ERK 1/2 on Thr 202/Tyr 204
results in its activation [32,33]. To determine whether
inhibition of MMP-1 by chemical inhibitors of the
MEK/ERK pathway correlated with decreased levels
of phospho-ERK 1/2 (pp42/44), Western blotting
with ERK 1/2 speci¢c antibodies for both the phos-
phorylated and non-phosphorylated forms was per-
formed. We found that in these melanoma cells,
ERK 1/2 is constitutively phosphorylated and that
Fig. 1. Northern blot analysis of MMP-1 and Erk phosphorylation state in the presence of increasing concentrations of PD098059
and U0126. (A) Dose response of PD098059 on MMP-1 mRNA levels. A2058 cells were grown until con£uent, washed with HBSS
and then placed in serum-free medium (0), serum-free medium with 0.05% DMSO (V) or serum-free medium with increasing concen-
trations of PD098059. After incubating for 24 h, total RNA was isolated, separated on an RNA gel, and probed as described in Sec-
tion 2. (B) Phosphorylation state of ERK (p42/p44) in the presence of increasing concentrations of PD098059. Cultures were treated
in the same manner mentioned above. At 24 h medium was removed and whole cell lysates were harvested in 200 Wl of 2USDS bu¡-
er. Whole cell extracts were separated on 10% SDS^PAGE gels, transferred to PVDF and probed for pp42/44 and total p42/44. (C)
Dose response of U0126 on MMP-1 mRNA levels. (D) Phosphorylation state of ERK (p42/44) in the presence of increasing concen-
trations of U0126. Methods are the same as for C. In D, total ERK 1/2 appears as a single band where two bands would be ex-
pected. The appearance of only one band may be attributed to several factors, including minimal separation of p42 and p44 (compare
D to B) and lower quantities of the p44 isoform (B).
BBADIS 62088 26-4-02
G.B. Tower et al. / Biochimica et Biophysica Acta 1586 (2002) 265^274268
phosphorylation of ERK 1/2 was inhibited com-
pletely at 5 WM by both PD098059 (Fig. 1B) and
U0126 (Fig. 1D).
Since the MEK/ERK pathway is only one of three
possible signaling cascades that comprise the MAP
kinase pathways, we wanted to ascertain whether the
ERK pathway was working alone or in conjunction
with either the p38 or JNK pathway, the stress-acti-
vated pathways in the MAPK family. The chemical
inhibitor, SB203580, inhibits the p38 pathway at low
concentrations (6 10 WM) [34] and has been shown
to inhibit the JNK pathway at higher concentrations
(v10 WM) [34]. In contrast to the inhibitor
PD098059, SB203580 had no e¡ect on the expression
of MMP-1, even at high concentrations of 20^40 WM
(data not shown). The lack of inhibition by
SB203580 indicates that the p38 and JNK pathways
are not involved in MMP-1 expression. Further, p38
and JNK are not phosphorylated in these cells (data
not shown), supporting the ¢nding that these two
pathways are not involved in this constitutive expres-
sion. Thus, our ¢ndings indicate a role for the ERK
1/2 pathway in the constitutive expression of MMP-1
in the A2058 melanoma cells.
As a ¢rst step in studying the mechanism of
PD098059 inhibition of MMP-1, RNA and whole
cell extracts were harvested at di¡erent times after
addition of 5 WM PD098059 to measure the kinetics
of this inhibition. As shown in Fig. 2, reduction of
the phosphorylated form of p42/44 (pp42/44) occurs
within 30 min of addition of PD098059. This inhibi-
tion of pp42/44 precedes inhibition of MMP-1
mRNA steady state by 1.5 h, with inhibition of
MMP-1 mRNA beginning approx. 2 h after addition
of PD098059. The lag in time suggests that there may
be an intermediary protein between the ERK 1/2
pathway and MMP-1 expression, which requires pro-
tein turnover before inhibition of MMP-1 occurs.
Alternatively, the half-life of the MMP-1 mRNA
may be long and even though an inhibition of tran-
scription may have already occurred, a decline may
not be seen until later.
3.2. Constitutive expression of MMP-1 requires the
de novo production of a protein
Activation of the ERK pathway can lead to the
expression of proteins (e.g. transcription factors) de
novo and/or to the phosphorylation of existing tran-
scription factors and kinases, thereby activating them
[32]. Furthermore, the activation of the ERK path-
way may culminate in the expression of MMP-1
through these mechanisms. In order to distinguish
between them, phosphorylation and protein synthesis
must be separated by inhibiting one function while
leaving the other intact. To investigate these possibil-
ities with respect to the constitutive synthesis of
MMP-1, cells were pretreated with 5 WM PD098059
or U0126 for 24 h. Inhibitors were then removed and
cells were allowed to recover for 12 or 24 h. During
the recovery period, selected cultures were treated
with cycloheximide to determine whether protein
synthesis was required to re-institute high constitu-
tive expression of MMP-1 mRNA. As expected, a
24 h treatment with PD098059 or U0126 completely
inhibited the expression of MMP-1 mRNA (Fig.
3A). In cells treated with cycloheximide alone, we
found that MMP-1 expression was slightly super-in-
duced, 1.16 and 1.37 times over mRNA levels in
control cells in serum-free medium (LH) at 12 and
24 h, respectively, although this increase was not sta-
tistically signi¢cant (P = 0.114). A similar ¢nding has
been reported for MMP-3 gene expression in cyclo-
heximide-treated cells and it has been suggested that
this increase may be due to stabilization of mRNA
[35].
Fig. 2. Inhibition of MMP-1 mRNA by PD098059 lags behind
reduction in the phosphorylated form of p42/44. A2058 cells
were grown until con£uent then transferred to serum-free me-
dium, alone, or with the addition of 5 WM PD098059. RNA
and whole cell extracts in 2USDS bu¡er were harvested at 0,
0.5, 1, 2, 4, 6, 8, 10, and 12 h. RNA blots were probed with
MMP-1 cDNA and protein blots were probed with antibodies
to pp42/44 and p42/44. Probed blots were autoradiographed, the
developed ¢lms were scanned into Adobe Acrobat and band in-
tensities were quantitated by NIH Image. A graphical represen-
tation of percent MMP-1 expression and pp42/44 was plotted
against time. 8, MMP-1 mRNA expression; E, pp42/44.
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Fig. 3A shows that by 12 or 24 h after removal of
PD098059 or U0126, expression of MMP-1 returned
to control levels in cells from which the inhibitors
had been removed without the subsequent addition
of cycloheximide, but was either minimal or absent
in the samples treated with cycloheximide. The small
amount of mRNA expression in samples that con-
tained cycloheximide can be attributed to incomplete
inhibition of translation as determined by 3H-leucine
incorporation, which was inhibited 85% (data not
shown). These results suggest that the constitutively
high expression of MMP-1 requires de novo protein
synthesis of a factor(s) that is depleted during the
24 h treatment with PD098059 or U0126.
To support this conclusion and to examine
whether the lack of MMP-1 mRNA recovery was
possibly due to a decrease in total ERK 1/2 or
ERK 1/2 activity, whole cell extracts from the pre-
vious experiment were probed for p42/44 and pp42/
44. In all samples from cycloheximide-treated cells,
there was an increase in the phosphorylated forms of
ERK compared to controls even when total levels of
ERK declined (Fig. 3B). Increased ERK phosphory-
lation may be the result of the reduction of a phos-
phatase due to cycloheximide [36], and the decrease
in the level of total ERK was probably a function of
decreased protein synthesis. Thus, these ¢ndings sup-
port the concept that PD098059 depleted a protein(s)
necessary for MMP-1 mRNA expression.
3.3. MMP-1 inhibition by PD098059 is
transcriptional, and the 1G/2G polymorphism is
inhibited through di¡erent mechanisms
To determine whether PD098059 is suppressing
MMP-1 gene expression by inhibiting transcription,
4.3 kb of promoter DNA containing either the 1G or
the 2G allele linked to a luciferase reporter were
transiently transfected into A2058 cells, which were
then treated with increasing concentrations of
PD098059. Fig. 4A shows that transcription of the
2G allele is enhanced compared to the 1G allele, in
keeping with our previous studies [20]. Further, tran-
scription of both the 1G and 2G promoter constructs
was inhibited in a dose-dependent manner.
PD098059 equally repressed expression from the
1G and 2G constructs, with approx. 50% inhibition
at 5 WM PD098059 (Fig. 4A), a concentration where
Fig. 3. The e¡ects of cycloheximide on MMP-1 transcription after inhibition with PD098059 and U0126. A2058 melanoma cells were
incubated in serum-free medium (LH) with or without 5 WM PD098059 or U0126 for 24 h. Post incubation, selected cultures were
transferred to serum-free medium with or without cycloheximide for either 12 or 24 h. (A) Northern blots of RNA were probed with
MMP-1 cDNA as described in Section 2. (B) Whole cell extracts were analyzed on a SDS^PAGE gel and probed for pp42/44 and to-
tal p42/44 as in Fig. 1. pp+, phosphorylated control; pp3, non-phosphorylated control.
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the endogenous mRNA was also repressed (Fig. 1A).
The slight discrepancy in the e¡ective concentration
of PD098059 inhibiting MMP-1 mRNA and lucifer-
ase protein may be a function of the di¡erences be-
tween these two assays. Since both the 1G and the
2G promoters were inhibited equally, this suggests
that the 2G SNP may not be the sole target of the
ERK 1/2 pathway.
To identify the DNA targets of ERK 1/2, a series
of deletion constructs ranging from 34372 bp to
31564 bp, containing either the 1G or the 2G allele
[20], were transiently transfected into cells with or
without PD098059. In all constructs, the 2G con-
struct showed higher expression compared to the
1G construct, and deletion of upstream sequences
did not diminish the fold increase of the 2G contain-
ing promoter over the 1G (Fig. 4B). Rather, deletion
of upstream DNA increased the fold expression of
the 2G over the 1G. Indeed, in the 4372 bp con-
struct, expression of the 2G DNA was 3.8 times
greater than that of the 1G, while in the deletion
constructs, expression of the 2G DNA compared to
that of the 1G DNA increased 7.2-, 6.0- and 8.6-fold,
in order of decreasing length (Fig. 4B). However,
Fig. 4. E¡ects of PD098059 on the 1G and 2G MMP-1 promoter constructs. (A) Dose^response curve of PD098059. Triplicate cul-
tures of A2058 melanoma cells were transiently transfected with the 4.3 kb promoter constructs containing either 1G or 2G as de-
scribed in Section 2. Cultures were harvested and analyzed for both reporter activity and transfection e⁄ciency. The fold expression
of 2G over 1G is located above the data sets being compared. DMSO (V) at 0.05% was used as the vehicle control. In all experi-
ments, data points were averaged from triplicates in three independent experiments and represent mean þ S.D. B^D represent data
from the same experiment. (B) Deletional analysis of 1G/2G promoter constructs. Triplicate cell cultures were transiently transfected
with deletion constructs and analyzed. (Inset) Comparison of construct deleted at 31546 bp, either untreated or treated with 10 WM
PD098059. Untreated construct is enlarged from B. (C) 2G deletion constructs treated with 10 WM PD098059. (D) Treatment of 1G
deletion constructs with 10 WM PD098059. (E) Mutational analysis of the AP-1 site at 31602 bp in 4372 bp MMP-1 promoter in cells
with or without 10 WM PD098059. The di¡erent levels of RLUs re£ect the fact that transfection e⁄ciency can vary from one experi-
ment to another.
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deleting the promoter to 31564 bp, which removes
the upstream AP-1 site at 31602 bp and the SNP at
31607 bp, drastically reduced expression, which was
not further inhibited by PD098059 (Fig. 4B). All
constructs containing 2G SNP were inhibited by
PD098059 (Fig. 4C). These ¢ndings con¢rm that
the increase in expression of the 2G promoter over
the 1G promoter is primarily due to the extra G at
31607 bp. In contrast, inhibition of reporter expres-
sion by PD098059 in the 1G deletion constructs was
only observed in the 4.3 kb construct. This ¢nding
suggests that in the absence of the 2G allele,
PD098059 may inhibit MMP-1 through a site up-
stream from 33292 bp (Fig. 4D) (see Section 4).
Finally, since AP-1 and ETS sites cooperate to
drive transcription [18,20,37,38], we used mutational
analysis to determine the role of the AP-1 site at
31602 bp. Thus, 4.3 kb constructs containing either
1G or 2Gs, each with a mutated AP-1 site at 31602
bp, were transiently transfected into cells with or
without PD098059. The wild-type constructs respond
as expected, with an increase in transcription by the
2G DNA over the 1G, and with an inhibition of
both (Fig. 4D) alleles with PD098059. However,
when the AP-1 site was mutated, there was no di¡er-
ence in the level of transcription between either con-
struct and PD098059 did not inhibit transcription
(Fig. 4E). Together, these data suggest that both
the ETS site (2Gs) at 31607 bp and the AP-1 site
at 31602 bp are needed to attain the enhanced tran-
scription seen in the 2G allele compared to the 1G.
In addition, both sites are necessary for the inhibi-
tion of the constructs containing the 2G SNP by
PD098059.
4. Discussion
In normal physiology, the expression of MMP-1 is
generally very low. During situations such as wound
healing, embryonic development and certain diseases,
expression of MMP-1 can be induced to high levels
by multiple stimuli, e.g. growth factors [19] and cy-
tokines [5]. Many inducers of MMP-1 activate the
MAPK signaling pathways and these pathways
have been shown to regulate MMP-1 [11,12,28,39].
However, some tumor cells, including the A2058
melanoma cells, express high levels of MMP-1 in
the absence of external stimulation [20,25,26]. In
this paper we show that this high expression is due
to a constitutively active MEK/ERK pathway, which
can be blocked by two chemical inhibitors of this
pathway, PD098059 and U0126. In contrast to other
studies, where MMP-1 is induced in chondrocytes
and ¢broblasts by in£ammatory cytokines [5,11],
the p38 and JNK pathways are not involved in the
expression of MMP-1 in the melanoma cells. Thus,
depending upon the cells and the stimuli, the signal/
transduction pathways leading to MMP-1 expression
di¡er, emphasizing that MMP-1 gene expression can
be controlled by multiple mechanisms.
The MAPK pathways can increase transcription
by two mechanisms: by increasing the activity of ki-
nases and transcription factors by phosphorylating
them, or by increasing the levels of these proteins
themselves [40,41]. When cells were treated for 24 h
with the MEK/ERK inhibitors and then given cyclo-
heximide after removal of inhibitors, they were un-
able to recover full expression of MMP-1. Therefore,
we can conclude that the expression of MMP-1 is
dependent on the de novo synthesis of a protein(s).
As yet, these proteins have not been identi¢ed,
although potential candidates include members of
the AP-1 and ETS families of transcription factors
that are expressed by these cells (U. Benbow et al.
(2001) submitted).
The AP-1 and ETS families of transcription fac-
tors are common targets of the MAPK pathway and
are stronger trans-activators when they bind to ad-
jacent sites and work in concert [19,42]. There are a
number of AP-1 and ETS sites in the MMP-1 pro-
moter [19,37,43], but the 2G polymorphism at
31607 bp produces an additional ETS site that is
adjacent to an existing AP-1 site at 31602 bp. Our
data suggest that PD098059 may be targeting this
site since the expression from the 2G constructs was
inhibited throughout the deletion series. Further-
more, in constructs containing the 1G polymor-
phism, only the 34.3 kb construct was inhibited
by PD098059, suggesting that in the absence of
the 2Gs at 31607 bp the MEK/ERK pathway tar-
gets a sequence upstream from 33292 bp. Potential
upstream sites for PD098059 inhibition in the 1G
construct are an AP-1 site at 33475 bp, and two
ETS binding sites at 33238 bp and 33908 bp. Thus,
in the absence of the 2G site at 31607 bp, the trans-
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activating factors may ¢nd alternative cis-activating
sequences within the MMP-1 promoter through
which they activate gene expression. Finally, when
sequences upstream from 31564 bp were removed,
or the AP-1 site at 31602 bp was mutated, regula-
tion by the MEK/ERK pathway was abolished.
Since AP-1 factors tether ETS proteins and increase
their binding a⁄nity, AP-1 factors are often neces-
sary for ETS proteins to transactivate transcription
and, thus, deletion of the AP-1 site at 31602 bp
may have deleterious e¡ects on the transcriptional
activity of the 2G SNP.
Since the downstream targets of ERK 1/2 are
often transcription factors, it is intriguing to spec-
ulate that this protein(s) is a transcription factor(s)
whose expression is controlled by the ERK 1/2 path-
way, which then regulates MMP-1 transcription.
Thus, inhibition of MMP-1 by ERK 1/2 inhibitors
would be a secondary event, as suggested in Fig. 2.
Furthermore, it will be important to determine
whether AP-1 or ETS family members are down-
regulated in response to PD098059, and whether
these transcription factors contribute to the consti-
tutive expression of MMP-1 by targeting these sites.
The possibility that the same factor(s) may be re-
sponsible for the expression of both alleles of the
promoter but target di¡erent sites in each promoter
and induce di¡erent levels of transcription is an in-
teresting concept. If both alleles are targeted by the
same factors, it may be possible to induce or repress
MMP-1 expression, whether the genotype is 1G
and/or 2G, by targeting the common factor, or the
pathways leading to its activity. Ultimately, by
understanding the mechanisms that cause high con-
stitutive expression of MMP-1, we may be able to
devise treatments that inhibit the pathways regulat-
ing MMP-1 production, and thus reduce the meta-
static ability of tumors.
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